Very good piece this morning on how the FDA plans to speed new gene-therapies. For anyone with CAR-T stocks like VYGR, FATE, ONCE, etc....it should be a much read. Basically the FDA is going to be more willing to accept more uncertainty in exchange for promising therapies in “devastating diseases.” Measures of longterm effectiveness could come in postmarket follow-ups. Well worth the three minutes to digest as will have forward impacts to immunotherapy pipelines and concerns....

Comments